29 August 2023 08:30Ziccum CEO Analyst interview part 2
In part two of her Analyst interview CEO Ann Gidner offers a deep dive into the second of the company’s recent milestone Feasibility agreements plus an analysis of mRNA, why it is generating such historic levels of investment, and how Ziccum’s...
25 August 2023 09:30Analyst interview with Ziccum CEO on significant milestones achieved
With two paid Evaluation agreements signed with world-leading mRNA partners, after having proven the LaminarPace technology for mRNA/LNP treatment, Q2 2023 was the most successful in Ziccum’s history. CEO Ann Gidner describes the company’s...
17 August 2023 09:05Ziccum to present at Investor Conference BioFuture 2023 in New York
Ziccum AB is to present at the BioFuture 2023 conference in New York City, October 4 – 6 2023, a key industry event attracting top-tier investors to evaluate innovators in biopharmaceuticals. Ziccum CEO Ann Gidner will present Ziccum’s unique...
Den 17 juli tillkännagav Ziccum ett nytt betalt utvärderingsprojekt - det andra avtalet signerat på bara två månader med ett stort globalt Pharma/Biotech-företag. Denna nyhet kom en dag före publiceringen av Ziccums...
20 July 2023 09:45Ziccums Q2-rapport - VD-uppdatering på svenska
Q2 2023 har utan tvekan varit ett av de mest spännande och produktiva kvartalen i Ziccums historia - med två betalda utvärderingsavtal, tre nya patentansökningar och fortsatt bekräftelse av bolagets mRNA/LNP-resultat. VD Ann...
18 July 2023 08:00ZICCUM AB (publ) Interim report Q2 2023
SIGNIFICANT EVENTS Q2 2023 (APRIL-JUNE) SIGNIFICANT EVENTS AFTER THE SECOND QUARTER OTHER EVENTS CEO statement Taking amazing strides together, landing two deals for Ziccum It is truly fantastic to now deliver great results in our key areas, having...
17 July 2023 11:43Ziccum signs Evaluation Agreement for Feasibility Study with major global Pharmaceutical Corporation
As of today, Ziccum AB (publ) (‘Ziccum’) has signed a new Evaluation Agreement with a major global Pharmaceutical Corporation. The agreement is to perform a funded Feasibility study aiming to develop thermostable dry powder formulations in...
Ziccum AB (publ) is sponsoring one of the most well-attended international events in the field of mRNA-based therapeutics in Boston MA, July 26-28. Ziccum CEO Ann Gidner will present the company’s unique drying technology for biopharmaceuticals...
Ziccum AB (publ) (‘Ziccum’) has received notification from CEPI (the Coalition for Epidemic Preparedness), that its joint Expression of Interest, submitted in partnership with an mRNA-focused biotech company in January 2023, has not been selected...
2 June 2023 12:10Ziccum appoints senior biopharma executive as new CFO
Ziccum AB (publ) has appointed Johny Humaloja as its new CFO. Johny is a financial executive with decades of experience in the biopharma and biotech industries in Europe and the US. He will assume his new position on June 15. CEO Ann Gidner: “Johny’s...
New Ziccum Board member Assoc. Prof. Per Gerde has over 55 peer-reviewed scientific papers and six patent families to his name. He is the original inventor of Ziccum’s drying technology for pharmaceuticals, LaminarPace, and an authority on aerosol...
25 May 2023 11:40Ziccum CEO to present at BioStock Life Science Spring Summit
The CEO presentation held at the Annual General Meeting of Ziccum AB on May 24th will also be given at BioStock Life Science Spring Summit on May 30-31, 2023 by CEO Ann Gidner. The presentation in Swedish will focus on the company’s recent major...
24 May 2023 13:50Bulletin from the Annual General Meeting of Ziccum AB (publ)
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Ziccum AB (publ) (“the Company”) on the 24th of May 2023 in Lund. Adoption of income statement and balance sheet and discharge from liability The...
24 May 2023 13:50Kommuniké från årsstämma i Ziccum AB (publ)
Ziccum AB (publ) (”Bolaget”) avhöll den 24 maj 2023 årsstämma i Lund. Vid stämman fattades bland annat följande beslut. Fastställande av årsbokslut och ansvarsfrihet Stämman beslutade att fastställa...
11 May 2023 14:20Strategin ger resultat med betald studie i samarbete med toppbolag: VD-intervju på svenska
VD-intervju på svenska Efter genombrott i mRNA-projektet och tre patentansökningar i ny IP-strategi som just rapporterats, kom nu det konkreta resultatet på bolagets starka nysatsningar med ny strategi: en betald Feasibility-studie signerad...
9 May 2023 17:50Ziccum signs Evaluation Agreement with Biopharmaceutical Corporation focused on mRNA technologies
Ziccum AB (publ) (‘Ziccum’) has signed an Evaluation agreement with a Biopharmaceutical Corporation focused on mRNA technologies to commence a Feasibility study regarding LaminarPace for ambient drying of mRNA/LNP materials and/or mRNA vaccine(s)...
9 May 2023 12:18Ziccums Q1-resultat: VD-uppdatering på svenska
Ziccums delårsrapport för första kvartalet 2023 visade ett företag som går mycket starkt framåt på flera fronter - med många nya affärsutvecklingsaktiviteter, liksom en fantastisk milstolpe, i form av...
Den 24 april 2023 offentliggjorde Ziccum AB (publ) (”Bolaget”) pressmeddelande innehållande kallelse till Bolagets årsstämma att hållas den 24 maj 2023. I kallelsen angavs att förslag avseende beslut enligt punkterna...
2 May 2023 08:30Ziccum AB filing three patent applications as part of new, expanded strategy to strengthen patent protection
Ziccum AB (publ) (‘Ziccum’) has filed the three first patent applications in a new series that will significantly strengthen the company’s intellectual property (IP) position. The new, expanded IP strategy will provide multi-layered...
26 April 2023 08:30ZICCUM AB (publ) releases Interim report Q1 2023
To read the digital Report click here: https://reports-en.ziccum.com/interim-report-q1-2023/ SIGNIFICANT EVENTS Q1 2023 (JAN-MARCH) On January 18, Ziccum announced that the company on 24 - 26 January would attend the mRNA-based Therapeutics Summit in...